TMCnet News
SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of AcelRx Pharmaceuticals, Inc.Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (Nasdaq: ACRX). If you purchased or otherwise acquired AcelRx shares, and would like more information about the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA (News - Alert) 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at [email protected]. The investigation focuses on whether AcelRx and certain of its officers and/or directors violated federal securities laws. On October 12, 2017, the Company advised investors that it received a complete response letter from the U.S. Food & Drug Administration ("FDA") regarding the Company's New Drug Application for DSUVIA for the treatment of moderate-to-severe acute pain. The FDA requested the collection of additional data on "at least 50 patients to assess the safety of DSUVIA" and recommended certain changes to the Directions for Use to address use-related errors. Following this news, the stock price of AcelRx dropped. If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at [email protected]. Goldberg Law PC represents investors around the world, and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171016006274/en/ |
